Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PARGP1 stands for “PARG pseudogene 1,” referring to a non-functional genomic locus that is similar in sequence to the protein-coding Poly(ADP-ribose) glycohydrolase (PARG) gene. Pseudogenes, by definition, are segments of DNA that resemble known genes but contain mutations or sequence interruptions that typically prevent them from producing a functional protein. While some pseudogenes or their RNA products can have regulatory roles, there is no current evidence or established knowledge linking PARGP1 to any biological function, disease, or therapeutic process. It is not a recognized therapeutic target or biomarker[3][4][6]. PARGP1 is best described as a pseudogene and not a molecular or therapeutic target. There is no evidence supporting its relevance as a biomarker, drug target, or disease-associated locus. It is likely included in error if referenced in the context of drug discovery or clinical development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PARG pseudogene 1 (PARGP1).